- « Previous
- Clinical Pharmacology
- Next »
Precedex
Clinical Pharmacology
Precedex
The safety and efficacy of Precedex® has been evaluated in two randomized, double-blind, parallel-group, placebo-controlled multicenter clinical trials in 754 patients being treated in a surgical intensive care unit (ICU). All patients were initially intubated and received mechanical ventilation. These trials evaluated the sedative properties of dexmedetomidine by comparing the amount of rescue medication (midazolam in one trial and propofol in the second) required to achieve a specified level of sedation (using the standardized Ramsay sedation scale) between Precedex® and placebo from onset of treatment to extubation or to a total treatment duration of 24 hours. The Ramsay Level of Sedation Scale is displayed in Table 2.
Table 2: Ramsay Level of Sedation Scale
| Clinical Score | Level of Sedation Achieved |
| 6 | Asleep, no response |
| 5 | Asleep, sluggish response to light glabellar tap or loud auditory stimulus |
| 4 | Asleep, but with brisk response to light glabellar tap or loud auditory stimulus |
| 3 | Patient responds to commands |
| 2 | Patient cooperative, oriented, and tranquil |
| 1 | Patient anxious, agitated, or restless |
In the first study, 175 patients were randomized to receive placebo and 178 to receive dexmedetomidine by intravenous infusion at a dose of 0.4 mcg/kg/hr (with allowed adjustment between 0.2 and 0.7 mcg/kg/hr) following an initial loading infusion of 1 (one) mcg/kg IV over 10 minutes. The study drug infusion rate was adjusted to maintain a Ramsay sedation score of ≥ 3. Patients were allowed to receive "rescue" midazolam as needed to augment the study drug infusion. In addition, morphine sulfate was administered for pain as needed. The primary outcome measure for this study was the total amount of rescue medication (midazolam) needed to maintain sedation as specified while intubated. Patients randomized to placebo received significantly more midazolam than patients randomized to dexmedetomidine (see Table 3).
A second prospective primary analysis assessed the sedative effects of dexmedetomidine by comparing the percentage of patients who achieved a Ramsay sedation score of ≥ 3 during intubation without the use of additional rescue medication. A significantly greater percentage of patients in the dexmedetomidine group maintained a Ramsay sedation score of ≥ 3 without receiving any midazolam rescue compared to the placebo group (see Table 3).
Table 3: Midazolam use as rescue medication during intubation
(ITT) Study One
| Placebo D N=175 |
Dexmedetomidine N=178 |
p-value | |
| Mean total dose (mg) of midazolam | 19 mg | 5 mg | 0.0011* |
| Standard deviation | 53 mg | 19 mg | |
| Categorized midazolam use | |||
| 0 mg | 43 (25%) | 108 (61%) | < 0.001** |
| 0-4 mg | 34 (19%) | 36 (20%) | |
| > 4 mg | 98 (56%) | 34 (19%) | |
| ITT (intent-to-treat) population includes all randomized
patients. *ANOVA model with treatment center. **Chi-square |
|||
Generic Name: Dexmedetomidine hydrochloride
- « Previous
- Clinical Pharmacology
- Next »
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Health Extras
Herbal First Aid
Herbal medicine is ancient, but only in recent years have many people started to take notice of its all natural healing powers. See more WebMD Videos »
